Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas), for metastatic castrate-resistant disease has driven considerable growth in the size of the prostate cancer market. Penetration of Zytiga and Xtandi (and other novel hormonal agents) in other patient populations (e.g., biochemical recurrent, non-metastatic castrate-resistant disease) will be major market drivers. Other therapies, including Xofigo (Bayer HealthCare) and Jevtana (Sanofi) offer non-hormonal treatment options. However, optimal sequencing of therapies in the crowded castrate resistant prostate cancer armamentarium is still under reconnaissance.
- How does treatment differ, if at all, between biochemically recurrent and non-metastatic castrate resistant prostate cancer patients? What secondary hormone manipulations, if any, are employed?
- What is the most preferred sequencing of treatment among the asymptomatic, and symptomatic metastatic castrate resistant prostate cancer patients?
- What are the main key drivers and obstacles to prescribing of the current therapies in the treatment of metastatic castrate-resistant prostate cancer?
- How does treatment duration of key therapies (e.g., LHRH agonists, Zytiga, and Xtandi) differ by clinical setting (e.g., newly diagnosed patients vs. biochemical recurrent vs. castrate-resistant) according to surveyed physicians?
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Primary research: Survey of 250 European oncologists and urologists (~50 in each of the EU5 countries) fielded in February 2017.
Key companies: Johnson & Johnson, Astellas Pharma (Medivation), Bayer Healthcare, Sanofi-Aventis
Key drugs: Xtandi, Xofigo, Jevtana, Zytiga
- Prostate Cancer - Current Treatment - Detailed, Expanded Analysis (EU)
Author(s): Swati Tyagi, M.Sc, MBA; Rachel Webster
Swati Tyagi, is a Senior Business Insight Analyst in the oncology team at the Decision Resources Group.
She comes with 8 years of work experience from the life sciences market research industry. She has in-depth expertise in competitive intelligence, secondary and primary research, and strategic projects across multiple oncology indications. Prior to joining the company, she was a delivery manager in a market research organization, where she was handling a major client engagement account and a dedicated team of senior and business analysts working for the specialty medicine brands of the client. She holds an M.Sc in biotechnology and MBA from Amity University, India.
Rachel Webster M.Sc., D.Phil., is a senior director in the oncology and biosimilars team at Decision Resources Group, where she manages a team of analysts in producing syndicated primary and secondary market research reports on a wide range of oncology indications. She also provides sales and client support for all oncology products.
Previously, Dr. Webster was a senior analyst in the oncology group at Decision Resources. Dr. Webster has extensive experience in market forecasting with detailed expertise in cancer immunotherapies, prostate cancer, gastric cancer, and malignant melanoma. Dr Webster is also experienced in conducting primary research with physicians and payers in a wide range of oncology indications across the major pharmaceutical markets. Prior to joining Decision Resources Group, Dr. Webster was a research scientist at Immunocore in the target validation group, where her research focused on identifying target antigens expressed in cancers and autoimmune diseases using a proprietary T-cell receptor (TCR) technology platform, molecular biology and phage display techniques. Dr. Webster obtained her D.Phil., in biochemistry, M.Sc. and M.A (Hons) in biological sciences, from the University of Oxford.